D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating restated by equities research analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a $15.00 target price on the stock. D. Boral Capital’s price objective would suggest a potential upside of 234.82% from the company’s previous close.

A number of other brokerages have also recently issued reports on COYA. BTIG Research increased their target price on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Wednesday, October 8th. Lake Street Capital reiterated a “buy” rating and set a $17.00 target price on shares of Coya Therapeutics in a research report on Wednesday, November 5th. Wall Street Zen upgraded shares of Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Coya Therapeutics in a research note on Monday, November 24th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Coya Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Coya Therapeutics Trading Up 4.7%

COYA opened at $4.48 on Wednesday. Coya Therapeutics has a 1-year low of $3.94 and a 1-year high of $8.29. The business has a 50 day moving average of $5.61 and a 200-day moving average of $5.97. The stock has a market capitalization of $93.72 million, a price-to-earnings ratio of -4.04 and a beta of 0.25.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. Equities analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Prosperity Wealth Management Inc. raised its holdings in shares of Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares during the period. JPMorgan Chase & Co. bought a new stake in shares of Coya Therapeutics during the third quarter valued at approximately $28,000. Lantern Wealth Advisors LLC acquired a new position in shares of Coya Therapeutics during the third quarter worth approximately $66,000. Jane Street Group LLC grew its position in Coya Therapeutics by 101.7% in the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares during the period. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Coya Therapeutics in the 2nd quarter valued at $119,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.